Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Appointment of New CCO

Cyprotex PLC ("Cyprotex" or the "Company")

Cyprotex appoints Simon Bury as Chief Commercial Officer

Appointment reflects enhanced focus on the development of strategic relationships

Cyprotex PLC (AIM:CRX), the drug discovery technology and information company, has appointed Mr Simon Bury to the role of Chief Commercial Officer.

Mr Bury, 51, joins Cyprotex from Shanghai ChemPartner Ltd, where he was Director of Business Development and responsible for growing the company's European preclinical services business. Mr Bury previously held the position of Business Development Director at Scottish Biomedical Ltd, where he managed the company's global business development team and had worldwide responsibility for revenue generation from drug discovery projects. During this period he oversaw the significant expansion of the company's worldwide customer base and was responsible for establishing new markets for Scottish Biomedical in Asia Pacific and North America.

Mr Bury has also previously held sales/business development managerial positions at Pharmacopeia Inc, Hewlett-Packard and Zymark Ltd.

The appointment of Mr Bury is in line with the Company's commitment to increase its focus on business development activities and to further develop strategic relationships with clients. During 2008, the Company restructured the global sales team to reflect the renewed emphasis on business development and appointed three new business development managers in the USA and two in Europe.

Commenting on today's announcement, Dr. Anthony Baxter, CEO of Cyprotex said:

“I am delighted to announce the appointment of Simon to the role of Chief Commercial Officer. His knowledge and experience of our industry, coupled with his extensive sales and marketing expertise, will undoubtedly strengthen our relationships with existing partners as well as developing new relationships with potential clients.”

Mr Bury commented:

“Cyprotex has developed a great reputation for delivering high quality ADMET/PK services to global pharmaceutical and biotech companies and I am very much looking forward to joining the Cyprotex team and to using my experience to further advance the business.”

For further information:
Cyprotex PLC

Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Tel: +44 (0)1625 505 100
ir@cyprotex.com
www.cyprotex.com

Noble & Company
John Llewellyn-Lloyd
john.llewellyn-lloyd@noblegp.com
Sam Reynolds
sam.reynolds@noblegp.com
Tel: +44 (0) 20 7763 2200
www.noblegp.com

Financial Dynamics
Ben Brewerton / John Dineen
Tel: +44 (0) 20 7831 3113
cyprotex@fd.com
www.fd.com

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close